Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Mounjaro, Zepbound shortage eases
End of Zepbound Shortage Threatens $1 Billion Knockoff Weight-Loss Shot Industry
Americans who turned to telehealth companies and compounding pharmacies for cheap versions of Eli Lilly & Co.’s weight-loss drugs are scrambling to figure out if they’ll still have access after US regulators signaled an end to their unfettered use.
Mounjaro, Zepbound shortage eases as supplies of weight loss drug rebound
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit cheaper copycat versions.
Eli Lilly's Mounjaro, Zepbound removed from FDA's shortage list
GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list. Senior Health Reporter Anjalee Khemlani reports more on the story and what it means for competitors,
Makers of Ozempic, Mounjaro race to ramp up supply amid skyrocketing demand for drugs for weight loss
At Dr. Louis Aronne’s weight loss center in New York City, the reactions to new medicines like Wegovy and Mounjaro can be extreme.
Lilly weight-loss drug copycats dealt blow as shortage ends
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., threatening to upend the many knockoffs that became popular when patients couldn’t find the brand-name medicines.
Lilly's weight-loss drug removed from FDA's shortage list
The U.S. Food and Drug Administration removed Eli Lilly's blockbuster weight-loss and diabetes drugs from its shortage list late on Wednesday, likely piling pressure on firms selling cheaper versions known as compounded drugs.
4d
Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Says
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
1h
on MSN
With Its GLP-1 Drugs No Longer in a Shortage, Is Now the Time to Buy Eli Lilly Stock?
While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second.
26m
Mounjaro will soon be available as a weight loss treatment on the NHS - here's what that means for patients
Now that Mounjaro has been authorised for use on the NHS, it will be key that access to specialist weight loss services is ...
ConsumerAffairs
4d
Mountjaro, Zepbound removed from FDA's shortage list
The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...
4d
Zepbound is no longer in shortage. That could hurt off-brand weight loss drug sellers
The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...
Kelly on MSN
13d
Zepbound Prescription Online: How to Safely Obtain Your Medication
As digital healthcare grows, obtaining medications like Zepbound through online prescriptions has become increasingly popular ...
pharmaphorum
4d
Mounjaro and Zepbound shortages over, declares FDA
The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...
5d
Mounjaro and Zepbound no longer in shortage
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
7h
on MSN
Billion-Dollar News for Eli Lilly Stock Investors
Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Eli Lilly
Mounjaro
GLP-1
Food and Drug Administration
National Health Service
Feedback